Biote Corp. - Class A Common Stock BTMD 深 滬
已收盤 07-18 16:00:00 美东时间
4.02
-0.150
-3.60%
華盛通- 最 高4.20
- 今 開4.20
- 成交量 8.82万股
- 最 低 4.01
- 昨 收 4.17
- 總市值 1.33亿
- 52周最高 8.03
- 市盈率 靜 43.65
- 換手率 0.00%
- 52周最低 3.04
- 委 比 32.82%
- 總股本 3307.33万
- 歷史最高 12.08
- 量 比 1.08
- 振 幅 4.56%
- 歷史最低 2.75
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biote Director Steven J. Heyer Resigns
biote ( ($BTMD) ) just unveiled an update. On June 2, 2025, Steven J. Heyer res...
06-05 20:46
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 10.9% to $0.67 durin...
05-28 05:06
Earnings Scheduled For May 7, 2025
Companies Reporting Before The Bell • Wallbox (NYSE:WBX) is estimated to report...
05-07 16:33
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Shares of Meta Platforms, Inc. (NASDAQ:META) rose sharply in pre-market trading...
05-01 17:17
Biote Reduces Marc Beer’s Salary Amid Transition
biote ( ($BTMD) ) has provided an update. On April 1, 2025, Marc Beer, Executiv...
04-25 04:54
Biote announces purchase of shares by directors and CEO
biote (NASDAQ:BTMD) said on Tuesday that several members of its Board of Directors, along with CEO Bret Christensen, have made open market purchases of the company's common stock, acquiring an aggrega...
03-19 05:47
美股大行评级 | 花旗：首予BioNTech SE(BNTX)"买入"评级，目标价145美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107226114384474112.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Zevra Therapeutics(ZVRA)"买入"评级，目标价从23美元升至25美元</p> <p>• Benchmark：维持E W Scripps(SSP)"买入"评级，目
03-14 09:45
Biote Sees FY25 Revenue $202M-$208M Vs $227.18M Est.; Adj. EBITDA $59M-$64M
The Company expects the following for fiscal 2025:($ in millions)2025 Guidance Ranges Revenue$202-$208Adjusted EBITDA2$59-642025 Procedure revenue is expected to increase approximately 2-4% from 2024.2025
03-13 22:48
Craig-Hallum Maintains Buy on Biote, Lowers Price Target to $8
Craig-Hallum analyst Alex Fuhrman maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $12 to $8.
03-13 21:37
Biote Corp. Reports Solid 2024 Financial Performance
Biote Corp. ( ($BTMD) ) has released its Q4 earnings. Here is a breakdown of th...
03-13 12:09
